AstraZeneca Shares Plunge Amidst Escalating Probe Concerns in China
2 months ago
AstraZeneca's stock price experienced its most significant decline in over three years, plunging sharply by 12%. This dramatic drop can be attributed to escalating fears surrounding a regulatory investigation in China involving the pharmaceutical giant. Investors reacted swiftly to the news, indicating a growing concern over potential implications for AstraZeneca’s operations and revenue in one of the world’s largest pharmaceutical markets.
Continue reading